Spectral Medical Inc. (Toronto) raised $10 million in stock sales to fund its clinical trial for Toraymyxin, a device that removes endotoxins from the bloodstream. The firm's offering relates to a purchase of $14.3 million at 70 cents a share by a consortium. Read More
